Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project

Abstract

BackgroundProstate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.MethodsFour thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.ResultsFour thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.ConclusionsWe provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput “omics” technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

“…The present study was limited by its retrospective design and incomplete assessment of family history, which depended on self‐reporting by patients and queries by physicians, which is affected by recall bias, adoption, education and the number of male family members . We found a much lower frequency of family history than reported for Western countries; this discrepancy might be attributable to differences in the prevalence of prostate cancer in Asian and Western populations, with the prevalence of familial prostate cancer in Japan being just 3.6–6.5% . However, the prevalence of family history was still lower than previous reports from Japan, which might partially be derived from incomplete assessment of family history.…”

“…24 We found a much lower frequency of family history than reported for Western countries; this discrepancy might be attributable to differences in the prevalence of prostate cancer in Asian and Western populations, 25 with the prevalence of familial prostate cancer in Japan being just 3.6-6.5%. 26,27 However, the prevalence of family history was still lower than previous reports from Japan, which might partially be derived from incomplete assessment of family history. Other limitations are that the number of affected family members limits the distinction of heredity from familial prostate cancer, and the ages at diagnosis of prostate cancer in family members were not available.…”

Prostate cancer

“…14 Higher PSA level was shown to predict an increased risk for more advanced clinical stage, adverse pathologic features, and worse disease-specific survival. 15 16 These findings are in keeping with our study where the Filipino group had a mean pre-op PSA level roughly three times that of the American group and was accompanied by more adverse pathologic features. Of these features, grade remains to be the most robust and well-studied parameter in prostate cancer where a direct association is seen between increasing GSs and biochemical failure with local and distant recurrence in both untreated and treated patients.…”

Overview of BioBank Japan follow-up data in 32 diseases

“…Several earlier studies on malignant neoplasms described relative survival rates after stratifying for some clinical variables, such as sex, presenting status, histological grade, and disease stage. Further detailed survival analysis on malignant neoplasms among the BBJ subjects with malignant neoplasms was also performed 27, 28, 29, 30, 31, 32. It is difficult to compare the results of relative survivals between the current and the previous studies, because of the different subject characteristics, such as ethnicity and life-style, and the differences in the health care system in other countries and the methods of enrollment used in Japan.…”